Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study

Published:2007-06 Issue:6 Volume:177 Page:2136-2140
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Lord R.¹²³⁴,Nair S.¹,Schache A.²,Spicer J.¹²³⁴,Somaihah Navita¹²³⁴,Khoo V.³,Pandha H.⁴

Affiliation:

1. Department of Oncology and Urology, St. George’s, University of London, London

2. Department of Urology, Frimley Park Hospital, United Kingdom

3. Academic Department of Urology, Royal Marsden Hospital, United Kingdom

4. Department of Oncology, Postgraduate Medical School, University of Surrey, Surrey, United Kingdom

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference16 articles.

1. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization;Zhang;Cancer,2004

2. Tumour inflammatory angiogenesis and its chemoprevention;Albini;Cancer Res,2005

3. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide;Lutsiak;Blood,2005

4. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin;Damber;Cancer Chemother Pharmacol,2005

5. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice;Hanahan;J Clin Invest,2000

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

2. Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence;Cancer Letters;2024-07

3. Drug Resistance and Cardiovascular Safety of Second-Generation Anti-Androgens in Patients with Advanced Prostate Cancer;Galen Medical Journal;2023-12-26

4. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC);Clinical Genitourinary Cancer;2023-11

5. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma;Digestive and Liver Disease;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3